ViiV showcased the potential of its clinical-proven study

Image Credit: ViiV Healthcare

Announcement 

The ViiV Healthcare, a leading worldwide HIV specialist company owned by GSK, along with Shionogi and Pfizer as the shareholders, showcased a clinical presentation of over 60 abstracts, involving data from its industry-popular long-standing HIV treatment and prevention portfolio. The presentation will be showcased at the 20^th European AIDS conference (EACS) from 15-18 October, held in Paris, France, and also at the IDWeek 2025 event from 19-22 October, held in Atlanta, Georgia, US.

Key highlights

The major highlights consist of its primary data from the phase 1 CLARITY crossover study. The study covers the comparability of the tolerability and acceptability of lenacapavir (LEN) injections and cabotegravir long-term (CAB LA) after a single dose. The latest tolerability effectiveness data for Vocabria Plus rekambys commercialized as Cabenuva in Australia, Canada, and the US, apretude and its planned data on the creative merger approach in HIV treatment is an indication. The indication that has prompted the company’s leadership in HIV long-standing innovation to come into force with an advanced solution.

New clinical data’s potency

At EACS, the new data will include the data from the existing primary analysis of its phase 1 CLARITY study, which will highlight the new data’s tolerability and acceptability of CAB LA vs LEN in accordance with a single dose. The study will spotlight clinically suitable changes in the injection site reactions (ISRs) after the participants' experience of the following administration.

The MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, Jean van Wyk, said, “The expansional depth potential of our data at IDWeek and EACS shows the positive impact of our therapies. The potential commitment of our dedication and pipeline to effectively meet the emerging needs of HIV is prioritized. The CLARITY study differentiates single-dose injections of lenacapavir and cabotegravir. The comparison provides crucial insights into the provider and patient preferences, encouraging qualified decisions and building on our exponential shelf of real-world evidence in long-standing HIV prevention and treatment.”

There will be numerous studies at IDWeek offering insights into the real-world data of CAB LA in the HIV prevention stage. Including the PrEPFACTS study that will unveil the US testing strategy and evidence of HIV. The data will explain how oral PrEP or CAB LA is equipped in the real world to help contribute to optimal HIV care and other findings by offering insights from a group that registers for most of the new HIV diagnoses among the women population in the US.